PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.
PDL BioPharma, Inc. halted visilizumab manufacturing after its Phase II/III clinical trials, attributing this decision to its lack of efficacy and unfavorable safety record relative to existing treatments.